Objective: We have previously reported the safety, efficient gene transfer, and favorable CA125 responses of individuals with recurrent ovarian cancer treated by p53 gene replacement with the adenoviral vector SCH 58500. The purpose of the present investigation was to evaluate the long -term follow -up of these heavily pretreated patients subsequent to SCH 58500 dosing. Methods: Patients ( n = 36 ) were treated with either single -dose SCH 58500 in the phase I study or with multiple doses ( MD ) of SCH 58500 over multiple cycles in combination of platinum -based chemotherapy in the phase I / II portion of the study. Five patients were initially treated in the single -dose group and re -enrolled in the MD group. The MD group was evaluated both without the reenrolled patients as MD1 ( n = 19 ), and as MD2 ( n = 24 ), which included them. Patients who were only treated on the single -dose arm were designated as SD ( n = 12 ). Most patients received additional chemotherapy at the discretion of their physicians on completion of the trial. The current analysis is a retrospective sequential cohort survival analysis. Results: The first patient was treated in March 1997 and the last patient completed SCH 58500 in September 1998. There was no difference in age at diagnosis, Karnofsky performance status, interval between diagnosis to SCH 58500, prior cycles or regimen of chemotherapy, platinum -free interval, percent platinum refractory patients, pretreatment CA125, or largest tumor volume between groups. Both MD groups had a slightly longer chemotherapy -free interval before SCH 58500 than the SD group. Median survival of individuals who received MD SCH 58500 with chemotherapy was 12 -13.0 months, compared to only 5 months for those treated with SD SCH 58500. There are 10 long -term survivors more than 20 months after MD treatment for recurrent disease compared to only 2 long -term survivors after SD SCH 58500. Conclusion: The 12 -to 13.0 -month median survival in a heavily pretreated population with recurrent ovarian cancer compares favorably to the 16 -month median survival for individuals treated with paclitaxel at the time of initial recurrence of this disease and is more than double the 5 -month survival seen with palliative radiotherapy or paclitaxel failure. These data suggest that further study of SCH58500 is clearly indicated.
D espite the addition of several new cytotoxic agents to our therapeutic armamentarium, the overall survival of individuals diagnosed with advanced -stage ovarian cancer remains disappointing. 1 -4 In general, cytotoxic agents rely on a beneficial therapeutic index to effect greater damage to metastatic ovarian cancer than to normal host cells. The growing knowledge base of specific gene defects associated with ovarian cancer, 5, 6 coupled with the observation that this disease responds to surgical cytoreduction 7 -10 and tends to remain confined to the abdominal cavity throughout its course, 11, 12 make it an attractive model for molecularly targeted therapeutics. We have recently demonstrated that mutation of the p53 tumor suppressor gene leads to compromised ovarian cancer survival. 13 The results of a phase I /II trial of intraperitoneal adenoviral -mediated p53 gene replacement in recurrent ovarian cancer demonstrated safety, tolerability of doses limited only by infusion volume, and the manufacturing process.
14 Most importantly, repetitive gene transfer was the norm following multiple courses of SCH 58500 despite the rapid development of an elevated antiadenoviral antibody titer. Favorable CA125 responses in the phase II portion of the study have encouraged us to evaluate the long -term follow -up of these patients. This analysis was not planned as part of the original trial and should be considered a nonrandomized sequential cohort retrospective analysis.
Methods
SCH 58500 is a replication -defective, recombinant, human adenoviral vector containing the cloned wild -type human p53 gene. 15 Between 3/ 12/ 97 and 6 /24 /98, 36 patients with recurrent ovarian, peritoneal, or fallopian tube cancer enrolled in either a phase I escalating single -dose study of SCH 58500 at 7.5Â10 10 to 7.5Â10 12 particles, or a multiple -dose (MD ) group of patients receiving sequential SCH 58500 ( two to five doses per cycle ) at 7.5Â10 12 to 7.5Â10 13 particles per dose, given either with intraperitoneal cisplatin (100 mg / m 2 ) or intravenous carboplatin / paclitaxel. The last dose of SCH 58500 was given in September 1998. Five patients elected to go onto the MD portion of the study from 1 to 8 months after completion of the phase I portion. The treatment schema is outlined in Figure 1 . Dose levels 1 -6 correspond to 7.5Â10 10 , 7.5Â10 11 , 2.5Â10 12 , 7.5Â10 12 , 2.5Â10 13 , 7.5Â10 13 particles/dose, respectively. Intraperitoneal delivery of SCH 58500 for 2-5 days per cycle at dose levels 4-6, and routine follow -up have been described. 14 Follow -up information was collected from the time of study entry until patient death or through 05 /21 /01. A standard definition of platinum resistance was used: progression of disease while receiving carboplatin or cisplatin, or recurrence of disease within 6 months of completion of therapy. 4, 16 The resistance is considered primary if it occurs during or following the initial treatment. The resistance is said to be secondary if it occurs during or following platinum retreatment of recurrent disease.
Statistical analysis of the association between clinical and treatment parameters between groups was evaluated using the chi -square test or Fisher exact test where appropriate. Student t test was used for comparison of the means. Survival curves were constructed using the Kaplan -Meier method and differences between curves were tested using the log rank test. All P values were two sided, and only those kLargest CT measurable lesion widthÂlength. #Includes four patients with primary platinum resistance and three patients with initial complete response to primary / secondary treatment with platinum but failure to respond to secondary or tertiary treatment. **Includes six patients with primary platinum resistance and five patients with initial complete response to primary / secondary treatment with platinum but failure to respond to secondary or tertiary treatment.
yyIncludes six patients with primary platinum resistance and eight patients with initial complete response to primary / secondary treatment with platinum but failure to respond to secondary or tertiary treatment.
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Ovarian cancer gene therapy RE Buller et al less than .05 were considered statistically significant. Statistical analyses were implemented using the SPSS 10.0 package ( SPSS, Chicago, IL ).
Results
Patients were grouped on the basis of entry into the singledose arm ( SD; n= 12 ) and compared to a cohort who received only multidose (MD ) SCH 58500 with chemotherapy ( MD1; n= 19), or MD, that included the five patients re -enrolled on MD following participation in the SD portion of the trial (MD2; n = 24). The three groups were heavily pretreated with chemotherapy based on the number of prior chemotherapy cycles and regimens. Aside from a longer chemotherapy-free interval for the MD groups, Table 1 shows that there was no difference in the age at diagnosis of the original ovarian cancer, baseline Karnofsky performance status ( KPS ), number of prior regimens or cycles of chemotherapy, the interval from diagnosis to study entry, the platinum -free interval, mean CA125 or largest CT measurable lesions before dosing with SCH 58500. Platinum -resistant tumor made up 58% of each group. The SD group contained three (25% ) patients who had received a . Platinum resistance could be subdivided into primary / secondary as follows: 25% /25%; 32% /26%; 25% /33% for the SD, MD1, MD2 groups, respectively.
FOLLOW-UP (MONTHS)
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The MD2 group contained 10 ( 42% ) long -term survivors !20 months after study entry, as opposed to only 2 (17% ) in the SD group. Potentially important parameters that characterize these long -term survivors are summarized in Table 2 . Six subjects had received more than two prior platinum -containing regimens. Six of the 12 ( 50% ) could be considered to have platinum -sensitive disease. The platinum -free interval from last treatment with any platinum drug to first dose of SCH 58500 averaged 10.3 months [ range: 10.9 -21.5 months ]. In contrast, the other six patients were considered to have platinum -resistant disease, based on persistent disease after a primary treatment regimen or recurrence less than 6 months after completion of primary or secondary platinum -based therapy ( average 4.4 months; range: 3.8-5.5 months ). The mean pre -SCH 58500 CA125 was 362 U /dl [range: 53 -1298 ]. Six patients did not have measurable disease on computed tomography ( CT ) so that the average, largest, CT-measurable lesion was 8.5 cm 2 [ range: 0-56 cm 2 ]. The SD group had only one patient without CT-measurable disease. Three of six patients treated with intraperitoneal cisplatin at 100 mg /m 2 are the three longest survivors at nearly 3 years. None of the three had CT-measurable disease. One of these was considered to have a platinum -resistant cancer. None had a pathologic complete response to this treatment regimen. *Progression -free interval from primary treatment 36 months. Seventy -four percent had a surgically documented complete primary response. yProgression -free interval from previous treatment 12 months. Median prior therapy duration -12 months, nine cycles. Actual number of regimens not reported: 28 / 30>4 cm 2 disease. zOnly patients with progression, or stable disease, or relapse within 6 months after platinum therapy are included. A platinum -resistant population. Median number of platinum -containing courses = 6.
xMean of eight prior courses of cisplatin. Median survival: responders = 15.1 months, nonresponders = 5.8 months. {Platinum resistant population: 44% primary failure, 37% secondary platinum failure after a primary minimal partial response. kMeasurable disease required for entry. Treatment interval > 6 months, 100% KPS, longer interval from first diagnosis correlate with better survival.
#Measurable disease required. **Includes both platinum -sensitive ( 37% ) and platinum -resistant ( 63% ) patients. Measurable disease required. yyIncludes approximately 53% platinum resistance rate in each arm. Measurable disease required. zzOnly 48 / 63 are epithelial ovarian cancers: 44 / 48 are platinum resistant; 21 / 48 have measurable disease. xxFifty -seven percent had >1 prior platinum regimens. All with measurable disease. 2 / 33 develop bowel obstruction. {{Median survival is 29 months for no residual disease or recurrent >12 months after primary treatment. This drops to 8 -9 months for < 2 cm residual disease or a recurrence < 12 months after primary treatment. With >2 cm residual disease, all are dead < 8 months, median survival only 2 months.
kkSingle -dose SCH 58500 escalated from 7.5Â10 10 to 7.5Â10 12 particles / dose. ##Multiple -dose SCH 58500 ( 2 -5 doses / cycle ) 7.5Â10 12 to 7.5Â10 13 particles / dose ( cycle 1 ) with cisplatin alone or carboplatin + paclitaxel added in cycles 2 and 3.
Ovarian cancer gene therapy RE Buller et al Figure 2 shows survival curves for these three treatment groups. The median survival for the SD group was only 5 months [range: 1. 
Discussion
It can be said that there are no cures for recurrent ovarian cancer. Nonetheless, isolated indolent cases of what might be considered ''chronic'' ovarian cancer are well known to all who treat this disease. In general, unless there has been a prolonged treatment-free interval of two or more years without exposure to platinum -containing chemotherapy regimens, the interim prognosis for recurrent disease is rather dismal. 1 -4,10,17 -25 None of the patients in the present study had a platinum -free interval of more than 23 months. Only three patients were chemotherapy-free for greater than 12 months before study entry. Two of these were among the 12 long -term survivors. Table 3 presents median survival data for treatment of recurrent ovarian cancer under a variety of conditions. Survival varies from approximately four and a half months for those treated with palliative radiotherapy to as long as 19 months following retreatment with platinum. Several studies 17, 18, 22 indicate that the longest survival will be associated with the longer platinum -free intervals. This may be secondary to the development of a new cancer due to a field effect, rather than a ''late recurrence'' of the original disease. 26 Failure to respond to secondary paclitaxel treatment 24 is associated with only a 5 -month median survival. This interval, as for those treated with palliative radiotherapy 25 or for hexamethylmelamine nonresponders, 20, 21 matches the median survival for our SD SCH 58500 group. In contrast, median survival for individuals treated with multiple doses of SCH 58500 plus platinum -based chemotherapy was 12 -13 months. Three individuals treated with intraperitoneal cisplatin and SCH 58500 lived nearly 3 years after dosing and one is still alive at 35.8 months. The heavily pretreated nature of all three groups suggests that the normal advantage to retreatment with the platinum drug plus multidose SCH 58500 may not be fortuitous. Furthermore, most of the patients had rather bulky disease. Jänicke et al 10 have shown that chemotherapy following secondary cytoreduction produces a median survival of only 2 months when residual disease is >4 cm 2 . All of those patients expired within 8 months. Fully 23/36 [64% ] of the patients in the current study exceeded this tumor volume.
This was not a randomized trial and potential differences between prior and subsequent chemotherapy following completion of SCH 58500 dosing (both SD and MD ) may have influenced outcome. Patients in all groups went on to receive a variety of chemotherapy regimens at the discretion of the physicians following SCH 58500. It should be noted that at least 5 of the 12 SD patients were treated on a platinum regimen after dosing with SCH 58500. Furthermore, the survival differences hold true even if the singledose patients who subsequently were treated with multiple doses of SCH 58500 and chemotherapy are excluded from analysis ( SD vs MD1 ).
None of the patients treated with SCH 58500 could be considered to have had a clinical complete response. Thus, prolonged survival relative to historical controls suggests that either the combination of chemotherapy plus SCH 58500 may be synergistic or that multiple doses of SCH 58500 may affect a change in the nature of the cancer contributing to a chronicity of disease that favorably impacts survival. Because a single dose of SCH 58500 is enough to create a prolonged elevation of antiadenoviral antibody titters, 14 we cannot rule out a potential therapeutic effect of multidosing with SCH 58500 secondary to a peritoneal immune response. The effects of the different chemotherapy regimens ( intraperitoneal cisplatin or intravenous carboplatin + paclitaxel ) independent of SCH 58500 cannot be evaluated in this already complicated trial. Additional studies suggest that the potential therapeutic benefit for MD patients is independent of platinum retreatment. 27 Further study of this gene -specific agent delivered by a replication -deficient adenoviral vector would appear to be clearly indicated.
